| Old Articles: <Older 4961-4970 Newer> |
|---|
 |
Chemistry World
July 9, 2008
James Mitchell Crow |
Pharma goes green to cut costs The pharmaceutical industry's current drive to curb spending is helping to speed the adoption of green chemistry, say experts in the industry.   |
The Motley Fool
July 9, 2008
Brian Lawler |
Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests. |
The Motley Fool
July 9, 2008
Brian Lawler |
ViroPharma Makes Its Case Rather than taking the more traditional route, ViroPharma has taken steps to try to make it significantly harder than normal for a generic-drug maker to attack its lead drug, Vancocin. |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
July 8, 2008
Brian Orelli |
Now That's the Way to Spin Off a Company The two spin-off companies formed from Abraxis Pharmaceutical, APP Pharmaceuticals and Abraxis BioScience, are worth almost double the value their parent had before the sale. |
The Motley Fool
July 8, 2008
Brian Orelli |
Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note. |
The Motley Fool
July 7, 2008
Brian Orelli |
And Then There Were 4 The number of drug-eluting stent players in the U.S. doubles with the addition of Medtronic's Endeavor and Abbott Labs' Xience V. |
The Motley Fool
July 3, 2008
Brian Lawler |
A Cubist Masterstroke Cubist Pharmaceuticals, until now a one-drug wonder, becomes a marketer of two compounds. |
The Motley Fool
July 3, 2008
Brian Lawler |
Celgene Savors the Schadenfreude Bad news for a rival is a bonanza for drugmaker Celgene. |
The Motley Fool
July 2, 2008
Brian Lawler |
DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development. |
| <Older 4961-4970 Newer> Return to current articles. |
